Date: {{$ActivityAssignDate}}

Dear Dr. {{$doctorName}},


Subject: Understanding the in-clinic usage/treatment practices of Moisturizers in dry skin conditions


A defective skin barrier enables entry of irritants, allergens, and microbes that, together with an exaggerated immune response, result in skin inflammation. Atopic dermatitis is the prototypic inflammatory skin condition with a defective skin-barrier function, which is characterized by increased trans-epidermal water loss (TEWL), decreased SC hydration, increased pH, and decreased sebum levels. Several other chronic inflammatory skin conditions associated with skin-barrier deficiencies include psoriasis, ichthyosis, asteatotic eczema, and contact dermatitis. Additionally, there is an age-related decline in skin-barrier function and resultant loss of water accumulation in the SC, ultimately leading to loss of hydration. Chronologically aged skin has globally decreased levels of SC lipids, NMFs, and water content


Moisturizers have been shown to help in restoration of the integrity of the stratum corneum, acting as a barrier to water loss and replacement of skin lipids and other compounds. Also, moisturizers are commonly used to reduce fine lines and make skin appear smooth and soft. But there is still a need to help improve the structure of dermis and epidermis by improving and stimulating collagen and elastin formation.


Hence, a moisturizer which not only helps in improving the barrier function, but also helps in stimulating collagen formation and reducing the skin damage would be of greater benefit. This Market Research survey (MRS) has been undertaken to understand ‘Understanding the in-clinic usage/treatment practices of Moisturizers in dry skin conditions.’


As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey questionnaire from you.


We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.



Yours truly,




Sun Pharmaceutical Industries Limited

Mr. Sunil Jajoo

VP & Cluster Head, Dermatology

Sun Pharma